ATE287945T1 - Herstellung und verwendung von dendritischen zellen - Google Patents

Herstellung und verwendung von dendritischen zellen

Info

Publication number
ATE287945T1
ATE287945T1 AT01994661T AT01994661T ATE287945T1 AT E287945 T1 ATE287945 T1 AT E287945T1 AT 01994661 T AT01994661 T AT 01994661T AT 01994661 T AT01994661 T AT 01994661T AT E287945 T1 ATE287945 T1 AT E287945T1
Authority
AT
Austria
Prior art keywords
dendritic cells
manufacturing
monocytes
cd11c
interferon
Prior art date
Application number
AT01994661T
Other languages
English (en)
Inventor
Michel Goldman
Emmanuel Bartholome
Cristel Buelens
Fabienne Willems
Original Assignee
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles filed Critical Univ Bruxelles
Application granted granted Critical
Publication of ATE287945T1 publication Critical patent/ATE287945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4233—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4235—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01994661T 2000-11-14 2001-11-14 Herstellung und verwendung von dendritischen zellen ATE287945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00870273 2000-11-14
PCT/EP2001/013189 WO2002040646A1 (en) 2000-11-14 2001-11-14 Generation and use of dendritic cells

Publications (1)

Publication Number Publication Date
ATE287945T1 true ATE287945T1 (de) 2005-02-15

Family

ID=8175855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01994661T ATE287945T1 (de) 2000-11-14 2001-11-14 Herstellung und verwendung von dendritischen zellen

Country Status (7)

Country Link
US (1) US7405076B2 (de)
EP (1) EP1334177B1 (de)
AT (1) ATE287945T1 (de)
AU (1) AU2002224851A1 (de)
DE (1) DE60108661T2 (de)
ES (1) ES2234928T3 (de)
WO (1) WO2002040646A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10231655A1 (de) * 2002-07-12 2004-02-26 Blasticon Biotechnologische Forschung Gmbh Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
WO2008121719A1 (en) * 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
FR2848565B1 (fr) 2002-12-16 2007-04-06 Ets Francais Du Sang Lignee de cellules dendritiques gen2.2
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101173871B1 (ko) * 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2006042177A2 (en) * 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
DE102007006736B4 (de) 2007-02-07 2012-01-12 Dagmar Briechle In-vitro Testkit zur tierversuchsfreien Bestimmung des sensibilisierenden Potentials einer Substanz
CA2709398C (en) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
US20090259160A1 (en) * 2008-04-10 2009-10-15 Therinject, Llc System and composition for dendritic cell therapy using pharmacologically active microcarriers
WO2011026041A2 (en) 2009-08-28 2011-03-03 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
EP2476440B1 (de) 2009-09-11 2017-08-02 Proyecto de Biomedicina Cima, S.L. Therapeutische zusammensetzungen zur behandlung hpv-induzierter erkrankungen
WO2012142597A1 (en) * 2011-04-15 2012-10-18 The Regents Of The University Of California A method for generating potent dendritic cells
US9273284B2 (en) 2011-04-19 2016-03-01 The Regents Of The University Of California Method for generating potent dendritic cells
KR102873947B1 (ko) * 2015-05-07 2025-10-22 베이롤 칼리지 오브 메드신 수지상 세포 면역요법
WO2021100828A1 (ja) * 2019-11-19 2021-05-27 マイキャン・テクノロジーズ株式会社 ヒト不死化ミエロイド系細胞を使用したｉｎ ｖｉｔｒｏにおける物質の安全性評価方法
KR20260036555A (ko) * 2023-07-05 2026-03-17 이뮤니티바이오, 인크. 성분채집 물질 중간체로부터 면역 이펙터 세포의 생체외 생성

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89662A (en) * 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
EP0983345A1 (de) * 1997-05-21 2000-03-08 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Methoden und zusammensetzungen zur herstellung von dendritischen zellen aus expandierten monozyten und zur aktivierung von t-zellen

Also Published As

Publication number Publication date
US7405076B2 (en) 2008-07-29
AU2002224851A1 (en) 2002-05-27
DE60108661T2 (de) 2006-01-05
WO2002040646A1 (en) 2002-05-23
ES2234928T3 (es) 2005-07-01
EP1334177B1 (de) 2005-01-26
EP1334177A1 (de) 2003-08-13
DE60108661D1 (de) 2005-03-03
US20040037807A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
ATE287945T1 (de) Herstellung und verwendung von dendritischen zellen
ATE289354T1 (de) Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
BR9910251A (pt) Estimulação hematopoiética
ATE464373T1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
AU2001291651A1 (en) Industrial-scale serum-free production of recombinant proteins in mammalian cells
CY1109099T1 (el) Δημιουργια δενδριτικων κυτταρων απο μονοκυτταρικα δενδριτικα προδρομικα κυτταρα με gm-csf απουσια επιπροσθετων κυτοκινων
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
AU2002366532A1 (en) In vitro production of dendritic cells from cd14+ monocytes
NZ600075A (en) Means and methods for influencing the stability of antibody producing cells
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
EE03955B1 (et) Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
ATE408020T1 (de) Verfahren zur herstellung von faktor vii
ATE380826T1 (de) Hybrid-hepatozyten-wachstumsfaktorgen mit hoher expressionseffizienz von zwei hepatozyten- wachstumsfaktor-heterotypen
MXPA03008882A (es) Composiciones y metodos utiles para la infeccion por hcv.
DE60021590D1 (de) Verwendung von baclofen zur behandlung von alkoholismus
MA27169A1 (fr) Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique
WO2002098361A3 (en) T cell induced tissue repair and regeneration
EP1818401A3 (de) Verfahren zur Beurteilung der Phagozytenfunktion und dessen Anwendung
ATE414762T1 (de) Herstellung kultivierter menschlicher mastzellen und basophilen zur hochdurchsatz-entdeckung kleiner arzneistoffmoleküle
DE69628743D1 (de) Levobupivacain und dessen verwendung als anästhetikum bei schwangeren frauen
AU2003288621A1 (en) Rna bioassay
WO2002094992A3 (en) Directed evolution of protein in mammalian cells
AU2001256404A1 (en) Novel plant glucosidase i and use thereof for producing recombinant proteins with modified glycosylation
ATE371722T1 (de) Zusammensetzungen und verfahren zur herstellung von antigen-präsentierenden zellen
WO2003076602A3 (fr) Siomerieux s.a. - inserm

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1334177

Country of ref document: EP

REN Ceased due to non-payment of the annual fee